Merck filed a biologics license application for sotatercept in pulmonary arterial hypertension & now the FDA has granted it priority review.
https://www.merck.com/news/merck-receives-priority-review-from-fda-for-new-biologics-license-application-for-sotatercept-an-activin-signaling-inhibitor-to-treat-adults-with-pulmonary-arterial-hypertension-pah/
I wrote about the drug last fall for Nature Medicine:
"BMPR-II regulates apoptosis and has anti-proliferative effects on pulmonary smooth muscle and endothelial cells. Sotatercept should assist BMPR-II in its tug-of-war with another TGF-beta family member, ActRIIA (which promotes proliferation), by selectively trapping activin pathway ligands. Unlike existing therapies that provide symptomatic management, sotatercept has the potential to be a curative treatment for pulmonary arterial hypertension by modifying the underlying causes of the disease."
